Patents by Inventor Robin Barbour

Robin Barbour has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190330316
    Abstract: The invention provides antibodies that specifically bind tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.
    Type: Application
    Filed: May 2, 2017
    Publication date: October 31, 2019
    Inventors: Robin BARBOUR, Philip James DOLAN, Yue LIU
  • Publication number: 20190330314
    Abstract: The invention provides antibodies that specifically bind tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.
    Type: Application
    Filed: May 2, 2017
    Publication date: October 31, 2019
    Inventors: Robin Barbour, Philip James Dolan, III, Yue Liu, Svetlana Alexander, Mark E. Renz
  • Publication number: 20190322728
    Abstract: The invention provides antibodies to tau. The antibodies inhibit or delay tau-associated pathologies and associated symptomatic deterioration.
    Type: Application
    Filed: May 2, 2017
    Publication date: October 24, 2019
    Inventors: Peter SEUBERT, Philip James DOLAN, III, Yue LIU, Robin BARBOUR
  • Publication number: 20190315843
    Abstract: The invention provides monoclonal antibody 5C1 and related antibodies. The 5C1 antibody binds to an epitope within residues 118-126 of ?-synuclein. The antibodies of the invention are useful, for example, for treating and/or diagnosing disorders associated with ?-synuclein, particularly accumulation of ?-synuclein deposits. Such disorders include Lewy body diseases, such as Parkinson's disease, Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Combined Alzheimer's and Parkinson disease, pure autonomic failure and multiple system atrophy (MSA).
    Type: Application
    Filed: April 16, 2019
    Publication date: October 17, 2019
    Applicant: PROTHENA BIOSCIENCES LIMITED
    Inventors: Robin Barbour, Kate Dora Games Thiel, Tarlochan S. Nijjar
  • Publication number: 20190277863
    Abstract: The invention provides an infrared assay which allows the secondary structure analysis of alpha-synuclein from complex fluids like serum, blood plasma or cerebrospinal fluid without prior isolation, concentration or pretreatment. The secondary structure profile provides an indication of the proportion of alpha-synuclein in aggregated form and/or extent of aggregation of alpha-synuclein in aggregated form.
    Type: Application
    Filed: December 1, 2017
    Publication date: September 12, 2019
    Applicant: PROTHENA BIOSCIENCES LIMITED
    Inventor: Robin BARBOUR
  • Publication number: 20190227082
    Abstract: The invention provides methods of detecting both total alpha-synuclein and S129 phosphorylated (pS129) alpha-synuclein using a donor complex, a first acceptor complex, and a second acceptor complex. The donor complex comprises an antibody that specifically binds to alpha-synuclein linked to a support and a donor label. The 4B12 antibody is an example of a suitable antibody in the donor complex. The first acceptor complex for detecting pS129 alpha-synuclein comprises an antibody that preferentially binds to pS129 alpha-synuclein linked to a support and a first acceptor label. The 11A5 antibody is an example of a suitable antibody in the first acceptor complex. The second acceptor complex for detecting alpha-synuclein comprises an antibody that binds to alpha-synuclein regardless of S129 phosphorylation. The LB509 antibody is an example of a suitable antibody in the second acceptor complex.
    Type: Application
    Filed: July 6, 2017
    Publication date: July 25, 2019
    Applicant: PROTHENA BIOSCIENCES LIMITED
    Inventors: Robin BARBOUR, Deniz KIRIK, Natalie Regina LANDECK
  • Patent number: 10301382
    Abstract: The invention provides monoclonal antibody 5C1 and related antibodies. The 5C1 antibody binds to an epitope within residues 118-126 of ?-synuclein. The antibodies of the invention are useful, for example, for treating and/or diagnosing disorders associated with ?-synuclein, particularly accumulation of ?-synuclein deposits. Such disorders include Lewy body diseases, such as Parkinson's disease, Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Combined Alzheimer's and Parkinson disease, pure autonomic failure and multiple system atrophy (MSA).
    Type: Grant
    Filed: August 21, 2018
    Date of Patent: May 28, 2019
    Assignee: PROTHENA BIOSCIENCES LIMITED
    Inventors: Robin Barbour, Kate Dora Games Thiel, Tarlochan S. Nijjar
  • Publication number: 20190062415
    Abstract: The invention provides monoclonal antibody 5C1 and related antibodies. The 5C1 antibody binds to an epitope within residues 118-126 of ?-synuclein. The antibodies of the invention are useful, for example, for treating and/or diagnosing disorders associated with ?-synuclein, particularly accumulation of ?-synuclein deposits. Such disorders include Lewy body diseases, such as Parkinson's disease, Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Combined Alzheimer's and Parkinson disease, pure autonomic failure and multiple system atrophy (MSA).
    Type: Application
    Filed: August 21, 2018
    Publication date: February 28, 2019
    Inventors: ROBIN BARBOUR, KATE DORA GAMES THIEL, TARLOCHAN S. NIJJAR
  • Publication number: 20180371067
    Abstract: The invention provides antibodies that specifically bind to the LG4-5 modules of the G domain of laminin ?4. The antibodies can preferentially stain cancer or tumor cells or tissue. The antibodies can be used for detecting cancer, evaluating the efficacy of a cancer therapy, treating cancer, and treating obesity or obesity-related diseases, among other applications.
    Type: Application
    Filed: May 29, 2018
    Publication date: December 27, 2018
    Inventors: Stephen Jed Tam, Yue Liu, Robin Barbour, Theodore Yednock, Kenneth Flanagan
  • Patent number: 10081674
    Abstract: The invention provides monoclonal antibody 5C1 and related antibodies. The 5C1 antibody binds to an epitope within residues 118-126 of ?-synuclein. The antibodies of the invention are useful, for example, for treating and/or diagnosing disorders associated with ?-synuclein, particularly accumulation of ?-synuclein deposits. Such disorders include Lewy body diseases, such as Parkinson's disease, Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Combined Alzheimer's and Parkinson disease, pure autonomic failure and multiple system atrophy (MSA).
    Type: Grant
    Filed: February 10, 2017
    Date of Patent: September 25, 2018
    Assignee: PROTHENA BIOSCIENCES LIMITED
    Inventors: Robin Barbour, Kate Dora Games Thiel, Tarlochan S. Nijjar
  • Patent number: 10059761
    Abstract: The invention provides antibodies that specifically bind to the LG4-5 modules of the G domain of laminin ?4. The antibodies can preferentially stain cancer or tumor cells or tissue. The antibodies can be used for detecting cancer, evaluating the efficacy of a cancer therapy, treating cancer, and treating obesity or obesity-related diseases, among other applications.
    Type: Grant
    Filed: March 12, 2015
    Date of Patent: August 28, 2018
    Assignee: PROTHENA BIOSCIENCES LIMITED
    Inventors: Stephen Jed Tam, Yue Liu, Robin Barbour, Theodore Yednock, Kenneth Flanagan
  • Publication number: 20180237516
    Abstract: The invention provides monoclonal antibody 3H6 and related antibodies. The 3H6 antibody binds to an epitope within residues 28-36 of IAPP. The antibodies of the invention are useful, for example, for treating disorders associated with IAPP accumulation, particularly accumulation of IAPP deposits. Such disorders include type 2 diabetes, metabolic syndrome, impaired insulin tolerance, impaired glucose tolerance, insulinomas, and related conditions.
    Type: Application
    Filed: February 9, 2018
    Publication date: August 23, 2018
    Applicant: PROTHENA BIOSCIENCES LIMITED
    Inventors: Robin Barbour, Tarlochan S. Nijjar
  • Publication number: 20180208646
    Abstract: The invention provides antibodies that specifically bind to the LG4-5 modules of the G domain of laminin ?4. The antibodies can preferentially stain cancer or tumor cells or tissue. The antibodies can be used for detecting cancer, evaluating the efficacy of a cancer therapy, treating cancer, and treating obesity or obesity-related diseases, among other applications.
    Type: Application
    Filed: March 12, 2018
    Publication date: July 26, 2018
    Inventors: Stephen Jed Tam, Yue Liu, Robin Barbour, Theodore Yednock, Kenneth Flanagan
  • Publication number: 20180171011
    Abstract: The invention provides monoclonal antibody 6B8 and related antibodies. The 6B8 antibody binds to an epitope within residues 3-12 of IAPP. The antibodies of the invention are useful, for example, for treating disorders associated with IAPP accumulation, particularly accumulation of IAPP deposits. Such disorders include type 2 diabetes, metabolic syndrome, impaired insulin tolerance, impaired glucose tolerance, insulinomas, and related conditions.
    Type: Application
    Filed: November 17, 2017
    Publication date: June 21, 2018
    Inventors: Robin Barbour, Yue Liu
  • Patent number: 9951131
    Abstract: The invention provides monoclonal antibody 3H6 and related antibodies. The 3H6 antibody binds to an epitope within residues 28-36 of IAPP. The antibodies of the invention are useful, for example, for treating disorders associated with IAPP accumulation, particularly accumulation of IAPP deposits. Such disorders include type 2 diabetes, metabolic syndrome, impaired insulin tolerance, impaired glucose tolerance, insulinomas, and related conditions.
    Type: Grant
    Filed: July 11, 2014
    Date of Patent: April 24, 2018
    Assignee: PROTHENA BIOSCIENCES LIMITED
    Inventors: Robin Barbour, Tarlochan S. Nijjar
  • Patent number: 9850302
    Abstract: The invention provides monoclonal antibody 6B8 and related antibodies. The 6B8 antibody binds to an epitope within residues 3-12 of IAPP. The antibodies of the invention are useful, for example, for treating disorders associated with IAPP accumulation, particularly accumulation of IAPP deposits. Such disorders include type 2 diabetes, metabolic syndrome, impaired insulin tolerance, impaired glucose tolerance, insulinomas, and related conditions.
    Type: Grant
    Filed: July 11, 2014
    Date of Patent: December 26, 2017
    Assignee: PROTHENA BIOSCIENCES LIMITED
    Inventors: Robin Barbour, Yue Liu
  • Publication number: 20170192017
    Abstract: The invention provides methods of detecting alpha-synuclein using a capture antibody and a reporter antibody. The capture antibody binds preferentially to full-length alpha-synuclein phosphorylated at residue 129 (PS129 alpha-synuclein) over unphosphorylated full-length alpha-synuclein. The 11A5 antibody is an example of a suitable capture antibody. The reporter antibody binds to an epitope within residues 40-55 of alpha-synuclein. The 23E8 antibody is an example of such an antibody. Because only a small proportion of alpha-synuclein is phosphorylated high sensitivity of detection below picomolar is advantageous.
    Type: Application
    Filed: August 25, 2016
    Publication date: July 6, 2017
    Inventors: Robin Barbour, Lynn R. Zieske
  • Publication number: 20170174777
    Abstract: The invention provides blood-brain barrier shuttles comprising monoclonal antibody 5C1 and related antibodies linked to a monovalent binding entity for a blood-brain barrier receptor. The 5C1 antibody binds to an epitope within residues 118-126 of alpha-synuclein. The antibodies are useful, for example, for treating and/or diagnosing synucleinopathies including Lewy body diseases, such as Parkinson's disease, diffuse Lewy body disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Alzheimer's and Parkinson's disease comorbidity, and pure autonomic failure, as well as multiple system atrophy (MSA).
    Type: Application
    Filed: April 8, 2015
    Publication date: June 22, 2017
    Inventors: Robin Barbour, Kate Dora Games-Thiel, Tarlochan S. Nijar, Wagner Zago, Olaf Mundigl, Jens Niewoehner, Georg Tiefenthaler
  • Publication number: 20170158755
    Abstract: The invention provides antibodies that specifically bind to the LG1-3 modules of the G domain of laminin ?4. The antibodies have the capacity to inhibit binding of laminin ?4 to MCAM. The antibodies can be used for inhibiting undesired immune responses, treatment of cancer, or treatment of obesity or obesity-related diseases, among other applications.
    Type: Application
    Filed: March 12, 2015
    Publication date: June 8, 2017
    Applicant: Prothena Biosciences Limited
    Inventors: Kenneth Flanagan, Stephen Jed Tam, Yue Liu, Theodore Yednock, Robin Barbour
  • Publication number: 20170152310
    Abstract: The invention provides monoclonal antibody 5C1 and related antibodies. The 5C1 antibody binds to an epitope within residues 118-126 of ?-synuclein. The antibodies of the invention are useful, for example, for treating and/or diagnosing disorders associated with ?-synuclein, particularly accumulation of ?-synuclein deposits. Such disorders include Lewy body diseases, such as Parkinson's disease, Diffuse Lewy Body Disease (DLBD), Lewy body variant of Alzheimer's disease (LBV), Combined Alzheimer's and Parkinson disease, pure autonomic failure and multiple system atrophy (MSA).
    Type: Application
    Filed: February 10, 2017
    Publication date: June 1, 2017
    Inventors: ROBIN BARBOUR, KATE DORA GAMES THIEL, TARLOCHAN S. NIJJAR